AR054125A1 - Derivados del fluoreno, composiciones farmaceuticas que los contienen y su utilizacion en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad de la proteina hsp90 - Google Patents

Derivados del fluoreno, composiciones farmaceuticas que los contienen y su utilizacion en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad de la proteina hsp90

Info

Publication number
AR054125A1
AR054125A1 ARP060101980A ARP060101980A AR054125A1 AR 054125 A1 AR054125 A1 AR 054125A1 AR P060101980 A ARP060101980 A AR P060101980A AR P060101980 A ARP060101980 A AR P060101980A AR 054125 A1 AR054125 A1 AR 054125A1
Authority
AR
Argentina
Prior art keywords
alkyl
optionally substituted
aryl
heteroaryl
heterocycloalkyl
Prior art date
Application number
ARP060101980A
Other languages
English (en)
Inventor
Patrick Mailliet
Luc Bertin
Fabienne Thompson
Fabienne Pilorge
Didier Bernard
Herve Minoux
Chantal Carrez
Helene Goulaouic
Thierry Gouyon
Jean-Marie Ruxer
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of AR054125A1 publication Critical patent/AR054125A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Uso de los mismos en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la proteína HSP9U y composiciones farmacéuticas que los contienen. Reivindicacion 1: Los productos de la formula (1), en la que: A1, A2, A3 y A4, idénticos o diferentes, representan CRa o N o NRb; en el cual Rb representa alquilo, alcoxi u OH; R1 y R1' son tales que: o bien R1 y R1' idénticos o diferentes son tales que uno de R1 y R1' representa un átomo de hidrogeno o de halogeno o un radical seleccionado entre alquilo C1-3, alcoxi C1-3, alquil-OH, CF3, ciano, carboxi y carboxamido; y el tro de R1 y R1' se selecciona del grupo constituido por H; halogeno; CF3; hidroxi; mercapto; nitro; amino; NH-OH ; NH-CO-H ; NH-CO-OH, NH-CO- Oalquilo, NH-CO-NH2; carboxi; CN; CO-NH2; X-(CH2)m-alquilo; X-(CH2)m-cicloalquilo; X-(CH2)m-heterocicloalquilo; X-(CH2)m-arilo o X-(CH2)m-heteroarilo con X = enlace sencillo, CH2, CH=CH, CH2-O, CH2-NH, CH2-C(O), CH2-C(O)-O, CH2-C(O)-NH, CH2-NH-(CO), CH2-NH-S(O), CH2- NH-S(O)2, O, S, NH, O-C(O), C(O)-NH1 -NH-C(O), -NH-C(O)-C(O)-, -NH-C(O)-NH-, NH-CS, NH-S(O) o NH-S(O)2, -NH-CO-CH2-O-; -NH-CO-CH2-S-CH2-CO-NH-; -NH-CO-(CH2)2-SO2-; -NH-CO-CH2-N(CH3)-CO-; con m = 0, 1 o 2, estando todos los radicales alquilo, cicloalquilo, heterocicloalquilo, arilo y heteroarilo opcionalmente sustituidos, conteniendo el radical cicloalquilo de 3 a 10 miembros, conteniendo el radical arilo de 6 a 10 miembros, y conteniendo los radicales heterocicloalquilo y heteroarilo, opcionalmente sustituidos, de 4 a 10 miembros de los cuales 1 a 4 son heteroátomos seleccionados entre O, S, N o NR3 en el cual R3 representa H o alquilo que está él mismo opcionalmente sustituido; o bien R1 y R'1 forman junto con los átomos de carbono a los cuales están unidos un radical =O; =S; =N-OH; =N-NH2; =N-NH-CO-NH2, =CH-OH; =Y1-(CH2)m-arilo o =Y1-(CH2)m-heteroarilo, en los cuales Y1 representa CH, CH-CO-, CH-CO-NH, N, N-O o N-NH, con m = 0, 1 o 2 y en los cuales arilo y heteroarilo son como se ha definido anteriormente y están opcionalmente sustituidos; o bien R1 R'1 forman junto con los átomos de carbono a los cuales están unidos un ciclo parcialmente saturado que consta de 4 a 6 miembros y que contiene eventualmente 1 a 3 heteroátomos seleccionados entre O, S, N o NR4 en el cual R4 representa H o alquilo que está él mismo opcionalmente sustituido; R2 y R'2, idénticos o diferentes, se seleccionan independientemente del grupo constituido por H, halogeno, CF3, nitro, ciano, alquilo, hidroxi, mercapto, amino, alquilamino, dialquilamino, alcoxi, alquiltio (metiltio), carboxi libre o esterificado por un radical alquilo, carboxamida, CO-NH(alquil) y CO N(alquil)2, estando opcionalmente sustituidos todos los radicales alquilo, alcoxi y alquiltio; p y p' idénticos o diferentes representan respectivamente los numeros enteros 1 a 4 y 1 a 3; Ra se selecciona del grupo constituido por H; halogeno; CF3; hidroxi; OCF3; SO2- NH2; SO2-NH(alk), SO2-N(alk)2; mercapto; nitro; amino; NH(alk); N(alk)2; NH-OH; NH-CO-H; NH-CO-NH2; carboxi libre o esterificado por un radical alquilo que está él mismo opcionalmente sustituido; CN; CO-NH2; Y-(CH2)n-alquilo; Y-(CH2)n-cicloalquilo, Y-(CH2)n-heterocicloalquilo, Y-(CH2)n- arilo o Y-(CH2)n-heteroarilo, en los cuales Y representa un enlace sencillo o bien =O, S, NH, O-C(O), C(O)-NH, -C(O)N(CH3)-; CO; NH-C(O), NH-S(O) o NH-S(O)2; con n = O, 1 , 2, o 3 radicales en los cuales los radicales alquilo, cicloalquilo, heterocicloalquilo, arilo y heteroarilo están opcionalmente sustituidos, el radical cicloalquilo contiene de 3 a 10 miembros, el radical arilo contiene de 6 a 10 miembros, y los radicales heterocicloalquilo, y heteroarilo, opcionalmente sustituidos, contienen de 4 a 10 miembros de los cuales 1 a 4 son heteroátomos seleccionados entre O, S, N o NR3 en el cual R3 representa H o alquilo que está él mismo opcionalmente sustituido; estando todos los radicales alquilo, alcoxi, alquiltio, cicloalquilo, heterocicloalquilo, arilo y heteroarilo de los sustituyentes de los productos de la formula (1) opcionalmente sustituidos; estando dichos productos de la formula (1) en todas las formas de tautomeros e isomeros posibles; racémicos, enantiomeros y diastereoisomeros, así como las sales de adicion con los ácidos minerales y orgánicos o con las bases minerales y orgánicos de dichos productos de la formula (1).
ARP060101980A 2005-05-19 2006-05-17 Derivados del fluoreno, composiciones farmaceuticas que los contienen y su utilizacion en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad de la proteina hsp90 AR054125A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0505037A FR2885904B1 (fr) 2005-05-19 2005-05-19 Nouveaux derives du fluorene, compositions les contenant et utilisation

Publications (1)

Publication Number Publication Date
AR054125A1 true AR054125A1 (es) 2007-06-06

Family

ID=36036699

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101980A AR054125A1 (es) 2005-05-19 2006-05-17 Derivados del fluoreno, composiciones farmaceuticas que los contienen y su utilizacion en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad de la proteina hsp90

Country Status (31)

Country Link
US (1) US7674795B2 (es)
EP (1) EP1888579B1 (es)
JP (1) JP4964874B2 (es)
KR (1) KR101288696B1 (es)
CN (1) CN101203518B (es)
AR (1) AR054125A1 (es)
AT (1) ATE518859T1 (es)
AU (1) AU2006248825B2 (es)
BR (1) BRPI0611424A2 (es)
CA (1) CA2608378C (es)
CR (1) CR9515A (es)
DO (1) DOP2006000112A (es)
EA (1) EA019027B1 (es)
FR (1) FR2885904B1 (es)
GT (1) GT200600206A (es)
HN (1) HN2006018410A (es)
IL (1) IL187163A (es)
JO (1) JO2753B1 (es)
MA (1) MA29493B1 (es)
MX (1) MX2007014443A (es)
MY (1) MY149037A (es)
NO (1) NO20076460L (es)
NZ (1) NZ563239A (es)
PA (1) PA8675701A1 (es)
PE (1) PE20061367A1 (es)
TN (1) TNSN07389A1 (es)
TW (1) TWI386406B (es)
UA (1) UA93203C2 (es)
UY (1) UY29549A1 (es)
WO (1) WO2006123061A2 (es)
ZA (1) ZA200709856B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1937643T3 (en) 2006-03-16 2016-10-10 Second Genome Inc Bicycloheteroarylforbindelser som p2x7-modulatorer og anvendelser deraf
FR2907453B1 (fr) * 2006-10-24 2008-12-26 Sanofi Aventis Sa Nouveaux derives du fluorene,compositions les contenant et utilisation
US8759819B2 (en) * 2007-11-22 2014-06-24 Idemitsu Kosan Co., Ltd. Organic electroluminescence device
JP5794912B2 (ja) * 2008-03-31 2015-10-14 カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ 供与体−受容体フルオレン骨格、それの方法及び使用
GB0809314D0 (en) * 2008-05-22 2008-07-02 Summit Corp Plc Compounds for treating muscular dystrophy
US8362268B2 (en) 2008-05-30 2013-01-29 University Of Notre Dame Du Lac Anti-bacterial agents from benzo[d]heterocyclic scaffolds for prevention and treatment of multidrug resistant bacteria
FR2932484B1 (fr) 2008-06-16 2010-06-18 Sanofi Aventis Nouveaux derives de pyrroloindole inhibiteurs d'hsp90, compositions les contenant et utilisation
EP2307342B1 (en) * 2008-07-02 2017-06-21 British Columbia Cancer Agency Branch Diglycidic ether derivative therapeutics and methods for their use
AR074797A1 (es) 2008-10-10 2011-02-16 Japan Tobacco Inc Compuesto de fluoreno , composiciones farmaceuticas , inhibidores de pdhk y pdhk2 , metodos de tratamiento , usos de los mismos y kit comercial
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
JP5940982B2 (ja) 2010-01-06 2016-06-29 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ アンドロゲンレセプター活性調節因子としての、ビスフェノール誘導体およびその使用
US9290485B2 (en) 2010-08-04 2016-03-22 Novartis Ag N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
WO2012145330A1 (en) * 2011-04-18 2012-10-26 The University Of British Columbia Fluorene-9-bisphenol compounds and methods for their use
CN102442973A (zh) * 2011-09-22 2012-05-09 华东理工大学 催化氧化伯醇闭环合成苯并咪唑和苯并噻唑化合物的方法
GB2515909B (en) * 2012-01-31 2020-07-15 Cambridge Display Tech Ltd Composition comprising a fluorescent light-emitting material and triplet-accepting polymer and use thereof
US9365510B2 (en) 2012-04-16 2016-06-14 British Columbia Cancer Agency Branch Aziridine bisphenol ethers and related compounds and methods for their use
NZ702169A (en) 2012-05-25 2016-10-28 Berg Llc The use of heat shock protein 90 (hsp90) modulators for the treatment of metabolic syndrome
RU2664532C2 (ru) 2013-03-15 2018-08-20 Джапан Тобакко Инк. Пиразоламидное соединение и его применения в медицине
PE20160091A1 (es) 2013-05-10 2016-03-03 British Columbia Cancer Agency Branch Derivados de ester de moduladores del receptor de androgeno y metodos para su uso
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
EP3044197B1 (en) 2013-09-09 2018-11-07 British Columbia Cancer Agency Branch Halogenated compounds for cancer imaging and treatment and methods for their use
KR102280686B1 (ko) 2014-02-11 2021-07-22 삼성전자주식회사 카바졸계 화합물 및 이를 포함한 유기 발광 소자
KR20220101015A (ko) * 2014-04-14 2022-07-18 아비나스 오퍼레이션스, 인코포레이티드 단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
EP3152307A4 (en) 2014-06-06 2018-05-02 Berg LLC Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta
US11426386B2 (en) 2014-12-05 2022-08-30 Case Western Reserve University Compositions and methods of modulating S-nitrosylation
WO2016090373A1 (en) 2014-12-05 2016-06-09 Case Western Reserve University Compositions and methods of modulating s-nitrosylation
JP6884100B2 (ja) 2015-01-13 2021-06-09 ブリティッシュ コロンビア キャンサー エージェンシー ブランチ がんの画像化及び治療用のヘテロ環式化合物ならびにそれらの使用方法
WO2016141458A1 (en) 2015-03-12 2016-09-15 British Columbia Cancer Agency Branch Bisphenol ether derivatives and methods for using the same
KR102691931B1 (ko) * 2015-06-04 2024-08-05 아비나스 오퍼레이션스, 인코포레이티드 단백질분해의 이미드계 조절인자 및 관련된 이용 방법
US20170298033A1 (en) 2016-04-15 2017-10-19 The University Of British Columbia Bisphenol derivatives and their use as androgen receptor activity modulators
CN114716377A (zh) 2016-07-29 2022-07-08 日本烟草产业株式会社 吡唑-酰胺化合物的制造方法
CA3076889A1 (en) 2017-09-25 2019-03-28 Case Western Reserve University Compositions and methods of reducing serum cholesterol and pcsk9
WO2019226991A1 (en) 2018-05-25 2019-11-28 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
WO2020005938A1 (en) 2018-06-25 2020-01-02 Case Western Reserve University Compositions and methods for treating tissue injury
EP3852750A4 (en) 2018-09-21 2022-05-11 Case Western Reserve University ALDOKETO REDUCTAE INHIBITORS AND THEIR USES
WO2020081999A1 (en) 2018-10-18 2020-04-23 Essa Pharma, Inc. Androgen receptor modulators and methods for their use
CN109574917B (zh) * 2018-12-03 2020-12-08 武汉尚赛光电科技有限公司 一种芴酮衍生物及其制备和应用
CA3125350A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Irreversible inhibitors of menin-mll interaction
WO2020142559A1 (en) 2018-12-31 2020-07-09 Biomea Fusion, Llc Inhibitors of menin-mll interaction
WO2020198712A1 (en) 2019-03-28 2020-10-01 Essa Pharma, Inc. Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
CN110981795B (zh) * 2019-12-18 2021-02-12 武汉世纪久海检测技术有限公司 一种利用2-氰基异烟酸甲酯制备2-氨酰基异烟酸的方法
AU2021255723A1 (en) 2020-04-17 2022-12-08 Essa Pharma, Inc. Solid forms of an N-terminal domain androgen receptor inhibitor and uses thereof
IL310717A (en) 2021-08-20 2024-04-01 Biomea Fusion Inc Crystalline form of N-[4-[4-(4-morpholinyl)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO ] -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, IRREVERSIBLE MENIN-MLL INHIBITOR FOR CANCER TREATMENT

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6015796A (en) * 1995-06-14 1997-01-15 Yamanouchi Pharmaceutical Co., Ltd. Fused imidazole derivatives and medicinal composition thereof
WO2002014315A2 (en) * 2000-08-14 2002-02-21 Ortho Mcneil Pharmaceutical, Inc. Substituted pyrazoles
JP4399265B2 (ja) * 2001-12-21 2010-01-13 ヴァーナリス(ケンブリッジ)リミテッド 3,4−ジアリールピラゾール、および癌の治療におけるそれらの使用
GB0228417D0 (en) 2002-12-05 2003-01-08 Cancer Rec Tech Ltd Pyrazole compounds
GB0229618D0 (en) 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
AU2003301226A1 (en) * 2002-12-20 2004-07-22 Pharmacia Corp Acyclic pyrazole compounds for the inhibition of mitogen activated protein kinase-activated protein kinase-2
WO2004072081A1 (en) * 2003-02-10 2004-08-26 Cellular Genomics, Inc. Certain 8-heteroaryl-6-phenyl-imidazo[1,2-a]pyrazines as modulators of kinase activity
DK1611112T3 (da) 2003-02-11 2012-11-19 Cancer Res Inst Isoxazolforbindelser som hæmmere af varmechokproteiner
GB0309637D0 (en) 2003-04-28 2003-06-04 Cancer Rec Tech Ltd Pyrazole compounds
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
US7538224B2 (en) * 2003-06-27 2009-05-26 Kyowa Hakko Kogyo Co., Ltd. Hsp90 family protein inhibitors
NZ546044A (en) 2003-08-29 2009-09-25 Vernalis Cambridge Ltd Pyrimidothiophene compounds
GB0323810D0 (en) * 2003-10-10 2003-11-12 Cancer Rec Tech Ltd Pyridothiophene compounds
US7538241B2 (en) * 2003-12-26 2009-05-26 Kyowa Hakko Kogyo Co., Ltd. Hsp90 family protein inhibitors
FR2884252B1 (fr) * 2005-04-08 2007-05-18 Aventis Pharma Sa Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90

Also Published As

Publication number Publication date
DOP2006000112A (es) 2007-01-31
EA200702531A1 (ru) 2008-04-28
GT200600206A (es) 2006-12-26
CN101203518B (zh) 2013-07-24
PA8675701A1 (es) 2006-12-07
FR2885904B1 (fr) 2007-07-06
WO2006123061A3 (fr) 2007-01-11
MA29493B1 (fr) 2008-05-02
NZ563239A (en) 2011-01-28
FR2885904A1 (fr) 2006-11-24
WO2006123061A2 (fr) 2006-11-23
TW200716633A (en) 2007-05-01
CR9515A (es) 2008-02-21
KR101288696B1 (ko) 2013-07-22
EA019027B1 (ru) 2013-12-30
ZA200709856B (en) 2009-12-30
UY29549A1 (es) 2006-12-29
IL187163A0 (en) 2008-02-09
EP1888579B1 (fr) 2011-08-03
CA2608378C (fr) 2013-12-31
HN2006018410A (es) 2010-03-05
US7674795B2 (en) 2010-03-09
JP2008540620A (ja) 2008-11-20
CA2608378A1 (fr) 2006-11-23
IL187163A (en) 2014-07-31
JP4964874B2 (ja) 2012-07-04
TNSN07389A1 (en) 2009-03-17
EP1888579A2 (fr) 2008-02-20
PE20061367A1 (es) 2007-01-08
MX2007014443A (es) 2008-02-11
ATE518859T1 (de) 2011-08-15
US20080153837A1 (en) 2008-06-26
UA93203C2 (ru) 2011-01-25
JO2753B1 (en) 2014-03-15
AU2006248825B2 (en) 2012-02-23
BRPI0611424A2 (pt) 2010-09-08
CN101203518A (zh) 2008-06-18
NO20076460L (no) 2008-02-19
TWI386406B (zh) 2013-02-21
KR20080025375A (ko) 2008-03-20
MY149037A (en) 2013-07-15
AU2006248825A1 (en) 2006-11-23

Similar Documents

Publication Publication Date Title
AR054125A1 (es) Derivados del fluoreno, composiciones farmaceuticas que los contienen y su utilizacion en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la actividad de la proteina hsp90
AR055606A1 (es) Derivados de benzoquinazolina
AR045595A1 (es) Composiciones utiles como inhibidores de proteinas quinasas
CY1118191T1 (el) Αναλογα δεοξυνοζιριμυκινης και οι χρησεις τους ως αναστολεις γλυκοζυλοκεραμιδασης
CO5721006A2 (es) Derivados de pirazolo-quinazolina, proceso para su preparacion y su uso como inhibidores de quinasa
EA200600811A1 (ru) НОВЫЕ ПРОИЗВОДНЫЕ ТЕТРАГИДРОСПИРО {ПИПЕРИДИН-2,7'-ПИРРОЛО [3,2-b]ПИРИДИНА} И НОВЫЕ ПРОИЗВОДНЫЕ ИНДОЛА, ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ РАССТРОЙСТВ, СВЯЗАННЫХ С 5-HT-РЕЦЕПТОРОМ
CL2004000174A1 (es) Compuestos derivados de malonamida n,n'-disustituidos; procedimiento de preparacion; composicion farmaceutica; y uso del compuesto en el tratamiento de la enfermedad de alzheimer.
NO20072978L (no) Nye betuinderivater, preparat derav og anvendelse derav
AR040257A1 (es) Profarmacos de aminoacidos excitadores
AR033306A1 (es) Compuestos
EA200602060A1 (ru) Производные пирролидин-2-она и пиперидин-2-она, используемые в качестве ингибиторов 11-бета-гидроксистероид-дегидрогеназы
RU2004122916A (ru) Производные 6-фторбицикло [3.1.0]гексана
CN102260188A (zh) 有机化合物
CY1105301T1 (el) Αρυλοσυμπυκνωμενες αζαπολυκυκλικες ενωσεις
NO20071137L (no) Nye piperidinderivater for behandling av depresjon
MA32206B1 (fr) Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
CY1108529T1 (el) Νεα αζαδικυκλικα παραγωγα, μεθοδος παρασκευης τους και φαρμακευτικες συνθεσεις που τα περιεχουν
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
BRPI0409110A (pt) derivados de 4-(4-heterociclilalcoxi)fenil-1-(heterociclil-carboni l)piridina e compostos relacionados como antagonistas de histamina h3 para o tratamento de doenças neurológicas tais como alzheimer
AR066972A1 (es) Derivados azapeptidicos
CY1111517T1 (el) Παραγωγα 1,3-δ1υδροιμιδαζολο-2-θειονης ως αναστολεις της ντοπαμινης-βητα-υδροξυλασης
AR053082A1 (es) DERIVADOS 8-PERFLUOROALQUIL-6,7,8,9-TETRAHIDROPIRIMIDO[1,2-A]PIRIMIDIN-4-ONA SUBSTITUIDOS NHIBIDORES DE GSK3BETA Y SU EMPLEO EN LA FABRICACIoN DE MEDICAMENTOS PARA EL TRATAMIENTO DE ENFERMEDADES NEURODEGENERATIVAS.
AR043485A1 (es) Derivados del 8'-piridinil-dihidrospiro-[cicloalquil]-pirimido[1,2a]pirimidin-6-ona y 8´-pirimidinil-dihidrospiro-[cicloalquil]-pirimido[1,2a]pirimidin-6-ona substituidos
RU2007128080A (ru) Производные пирролидиния в качестве мускариновых рецепторов мз
PA8573501A1 (es) Derivados de benzoxazina y su empleo

Legal Events

Date Code Title Description
FC Refusal